- Knowledge center
In principle, any RNA molecule in the transcriptome can be inhibited using nucleic acid based drugs, using for instance antisense technology. The newest generation of such nucleic acid based drugs are self-delivering, obviating the need for a delivery vehicle to cross cell membranes in the body and bypassing a major challenge in targeted drug development.
Once inside the cell, these drugs typically display high target-specificity, being able to distinguish a single nucleotide mismatch. Compared to small molecules, rational drug development using nucleic acid based drugs has a much faster development track.
Speed up your antisense oligo drug development with our unique massively parallel
in vitro antisense oligo efficacy screen, using a fully optimized high-throughput workflow.
Biogazelle has extensive experience with various antisense technologies to modulate RNA expression. Through four unique modules, we provide expertise to support your antisense oligonucleotide (ASO) drug development pipeline.